139 lines
43 KiB
Text
139 lines
43 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK44814">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK44814/?report=reader">
|
|
<meta name="ncbi_pagename" content="186Re-Labeled [N-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V) - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>186Re-Labeled [N-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V) - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/sos186re/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/MAMAHBP186Re/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="186Re-Labeled [N-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V)">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2010/06/03">
|
|
<meta name="citation_author" content="Arvind Chopra">
|
|
<meta name="citation_pmid" content="20642012">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK44814/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="186Re-Labeled [N-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V)">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Arvind Chopra">
|
|
<meta name="DC.Date" content="2010/06/03">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK44814/">
|
|
<meta name="description" content="Bisphosphonates (BPs) or nitrogen-containing bisphosphonates (NBPs) are often used for the management of pain palliation and disorders related to skeletal tissue, including those arising from cancer metastases, because these compounds have a very high affinity for hydroxyapatite (HA), a component of the bone matrix. These phosphonates or their derivatives tend to accumulate in osteoclasts located at areas of increased bone metabolism by inhibiting the enzyme farnesyl diphosphate (or pyrophosphate) synthase, an important regulatory enzyme of the cellular mevalonate pathway, which is involved in protein prenylation (1). The molecular mechanism of action of BPs and the NBPs has been described by Drake et. al. (2). Several BPs and NBPs are commercially available for clinical use to treat different bone disorders, and there are ongoing clinical trials approved by the United States Food and Drug Administration to evaluate these compounds for the treatment of various bone ailments. In addition, BPs are often labeled with 99mTc or 186/188Re and used for the imaging and treatment of pain as a result of bone metastases from cancer such as that of the breast or the prostate (3). However, these compounds have limited efficacy primarily because they exist either as a mixture of anionic compounds with varying properties (e.g., 99mTc- labeled methyl diphosphonate (MDP)) or are unstable (e.g., 86Re-labeled 1-hydroxyethylidene-1,1-diphosphonate) under in vivo conditions, resulting in a reduced uptake at targeted bone areas and an increased accumulation in non-target soft tissue such as the gastric lining of the stomach (4). The limited clinical utility of radiolabeled BPs was suggested to be caused by the dual activities exhibited by the compounds: one phosphonate group acts as a radionuclide chelator, and the other phosphonate group binds to the target(s).Therefore, due to the close proximity of the two groups, one activity may be interfering with the other (4).">
|
|
<meta name="og:title" content="186Re-Labeled [N-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V)">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Bisphosphonates (BPs) or nitrogen-containing bisphosphonates (NBPs) are often used for the management of pain palliation and disorders related to skeletal tissue, including those arising from cancer metastases, because these compounds have a very high affinity for hydroxyapatite (HA), a component of the bone matrix. These phosphonates or their derivatives tend to accumulate in osteoclasts located at areas of increased bone metabolism by inhibiting the enzyme farnesyl diphosphate (or pyrophosphate) synthase, an important regulatory enzyme of the cellular mevalonate pathway, which is involved in protein prenylation (1). The molecular mechanism of action of BPs and the NBPs has been described by Drake et. al. (2). Several BPs and NBPs are commercially available for clinical use to treat different bone disorders, and there are ongoing clinical trials approved by the United States Food and Drug Administration to evaluate these compounds for the treatment of various bone ailments. In addition, BPs are often labeled with 99mTc or 186/188Re and used for the imaging and treatment of pain as a result of bone metastases from cancer such as that of the breast or the prostate (3). However, these compounds have limited efficacy primarily because they exist either as a mixture of anionic compounds with varying properties (e.g., 99mTc- labeled methyl diphosphonate (MDP)) or are unstable (e.g., 86Re-labeled 1-hydroxyethylidene-1,1-diphosphonate) under in vivo conditions, resulting in a reduced uptake at targeted bone areas and an increased accumulation in non-target soft tissue such as the gastric lining of the stomach (4). The limited clinical utility of radiolabeled BPs was suggested to be caused by the dual activities exhibited by the compounds: one phosphonate group acts as a radionuclide chelator, and the other phosphonate group binds to the target(s).Therefore, due to the close proximity of the two groups, one activity may be interfering with the other (4).">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK44814/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/MAMABP186Re/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK44814/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E70CE7D63F7B100000000010D00E6.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK44814/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/sos186re/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">186Re-Labeled [N-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V)</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/MAMAHBP186Re/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK44814/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK44814/&text=186Re-Labeled%20%5BN-%5B2%5B%5B3-(3%2C3-diphosphonopropylcarbamoyl)propyl%5D-2-thioethylamino%5Dacetyl%5D-2-aminoethylenethiolat..."><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK44814/?report=classic">Switch to classic view</a><a href="/books/NBK44814/pdf/Bookshelf_NBK44814.pdf">PDF (139K)</a><a href="/books/NBK44814/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK44814%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E70CE7D63F7B100000000010D00E6.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK44814_"><span class="title" itemprop="name"><sup>186</sup>Re-Labeled [<i>N</i>-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V)</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm"> [<sup>186</sup>Re]MAMA-BP</div><p class="contribs">Chopra A.</p><p class="fm-aai"><a href="#_NBK44814_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figMAMABP186ReTncChemicalname186ReLabel"><a href="/books/NBK44814/table/MAMABP186Re.T.nc_Chemical_name186ReLabel/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobMAMABP186ReTncChemicalname186ReLabel"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="MAMABP186Re.T.nc_Chemical_name186ReLabel"><a href="/books/NBK44814/table/MAMABP186Re.T.nc_Chemical_name186ReLabel/?report=objectonly" target="object" rid-ob="figobMAMABP186ReTncChemicalname186ReLabel">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="MAMABP186Re.Background"><h2 id="_MAMABP186Re_Background_">Background</h2><p>[<a href="/pubmed?term=dipycolylamine%20alendronate&cmd=DetailsSearch" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Bisphosphonates (BPs) or nitrogen-containing bisphosphonates (NBPs) are often used for the management of pain palliation and disorders related to skeletal tissue, including those arising from cancer metastases, because these compounds have a very high affinity for hydroxyapatite (HA), a component of the bone matrix. These phosphonates or their derivatives tend to accumulate in osteoclasts located at areas of increased bone metabolism by inhibiting the enzyme farnesyl diphosphate (or pyrophosphate) synthase, an important regulatory enzyme of the cellular mevalonate pathway, which is involved in protein prenylation (<a class="bibr" href="#MAMABP186Re.REF.1" rid="MAMABP186Re.REF.1">1</a>). The molecular mechanism of action of BPs and the NBPs has been described by Drake et. al. (<a class="bibr" href="#MAMABP186Re.REF.2" rid="MAMABP186Re.REF.2">2</a>). Several BPs and NBPs are commercially available for clinical use to treat different bone disorders, and there are ongoing <a href="http://clinicaltrials.gov/ct2/results?term=bisphosphonates" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">clinical trials</a> approved by the United States Food and Drug Administration to evaluate these compounds for the treatment of various bone ailments. In addition, BPs are often labeled with <sup>99m</sup>Tc or <sup>186/188</sup>Re and used for the imaging and treatment of pain as a result of bone metastases from cancer such as that of the breast or the prostate (<a class="bibr" href="#MAMABP186Re.REF.3" rid="MAMABP186Re.REF.3">3</a>). However, these compounds have limited efficacy primarily because they exist either as a mixture of anionic compounds with varying properties (e.g., <sup>99m</sup>Tc- labeled methyl diphosphonate (MDP)) or are unstable (e.g., <sup>86</sup>Re-labeled 1-hydroxyethylidene-1,1-diphosphonate) under <i>in vivo</i> conditions, resulting in a reduced uptake at targeted bone areas and an increased accumulation in non-target soft tissue such as the gastric lining of the stomach (<a class="bibr" href="#MAMABP186Re.REF.4" rid="MAMABP186Re.REF.4">4</a>). The limited clinical utility of radiolabeled BPs was suggested to be caused by the dual activities exhibited by the compounds: one phosphonate group acts as a radionuclide chelator, and the other phosphonate group binds to the target(s).Therefore, due to the close proximity of the two groups, one activity may be interfering with the other (<a class="bibr" href="#MAMABP186Re.REF.4" rid="MAMABP186Re.REF.4">4</a>).</p><p>In an effort to solve the stability problems observed with the <sup>186</sup>Re-labeled NBPs, Ogawa et al. developed two new NBPs, <sup>186</sup>Re-[<i>N</i>-[2-[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V) ([<sup>186</sup>Re]MAMA-BP) and its hydroxylated derivative, <sup>186</sup>Re-[<i>N</i>-[2-[[4-[(4-hydroxy-4,4-diphosphonobutyl)amino]-4-oxobutyl]-2-thioethylamino]acetyl]-2-aminoethanethiolate] oxorhenium (V) ([<sup>186</sup>Re]MAMA-HBP) (<a class="bibr" href="#MAMABP186Re.REF.3" rid="MAMABP186Re.REF.3">3</a>). The investigators then compared the two compounds for their affinity to HA under <i>in vitro</i> conditions and studied the biodistribution of the radiochemicals in normal mice. This chapter presents the results obtained with [<sup>186</sup>Re]MAMA-BP. Results obtained with [<sup>186</sup>Re]MAMA-HBP are presented in a separate chapter of MICAD (<a class="bibr" href="#MAMABP186Re.REF.5" rid="MAMABP186Re.REF.5">5</a>).</p></div><div id="MAMABP186Re.Synthesis"><h2 id="_MAMABP186Re_Synthesis_">Synthesis</h2><p>[<a href="/pubmed?term=nitrogen%20containing%20bisphosphonate%20synthesis&cmd=DetailsSearch" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>A <sup>186</sup>Re-glucoheptonate ligand exchange reaction was used for the synthesis of [<sup>186</sup>Re]MAMA-BP and <sup>186</sup>Re-1-hydroxyethylidene-1,1-diphosphonate ([<sup>186</sup>Re]-MAMA-HEDP; used as a control in the various studies) and is detailed elsewhere (<a class="bibr" href="#MAMABP186Re.REF.6" rid="MAMABP186Re.REF.6">6</a>). The radiochemical yield of [<sup>186</sup>Re]MAMA-BP was reported to be between 21.3 ± 4.5 and 32.0 ± 4.1% with a purity of 96.4 ± 1.4%. Specific activity of the radiolabeled compounds was not reported.</p></div><div id="MAMABP186Re.In_Vitro_Studies_Testing_in"><h2 id="_MAMABP186Re_In_Vitro_Studies_Testing_in_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/pubmed?term=nitrogen%20containing%20bisphosphonate%20in%20vitro%20stability&cmd=DetailsSearch" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The <i>in vitro</i> stability of [<sup>186</sup>Re]MAMA-BP after a 24-h incubation in 0.1 M phosphate-buffered saline (pH, 7.0) saturated with 95% O<sub>2</sub> and 5% CO<sub>2</sub> at 37°C was reported to be 81.8 ± 1.7% as determined with reversed-phase high-performance liquid chromatography or thin-layer chromatography. Under the same conditions, the stability of [<sup>186</sup>Re]MAMA-HBP was reported to be 75.55 ± 1.57%.</p><p>The HA binding of [<sup>186</sup>Re]MAMA-BP was determined by using different amounts (1–25 mg/mL) of commercially available HA beads suspended in Tris/HCl-buffered saline (pH, 7.4) as described by Ogawa et al. (<a class="bibr" href="#MAMABP186Re.REF.3" rid="MAMABP186Re.REF.3">3</a>). The percent of HA binding was determined with an equation given elsewhere (<a class="bibr" href="#MAMABP186Re.REF.3" rid="MAMABP186Re.REF.3">3</a>). Approximately 40% of [<sup>186</sup>Re]MAMA-BP bound to the HA beads at the lowest concentration (compared with ~70% for [<sup>186</sup>Re]MAMA-HBP) and increased to ~95.0% at the highest concentration (compared with ~97.5% for [<sup>186</sup>Re]MAMA-HBP). Results from this study indicated that [<sup>186</sup>Re]MAMA-HBP had a higher affinity for HA than [<sup>186</sup>Re]MAMA-BP.</p></div><div id="MAMABP186Re.Animal_Studies"><h2 id="_MAMABP186Re_Animal_Studies_">Animal Studies</h2><div id="MAMABP186Re.Rodents"><h3>Rodents</h3><p>[<a href="/pubmed?term=nitrogen%20containing%20bisphosphonate%20rodentia&cmd=DetailsSearch" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>The biodistribution of [<sup>186</sup>Re]MAMA-BP and [<sup>186</sup>Re]MAMA-HBP was investigated in normal, male ddY mice after intravenous administration of the respective labeled compounds (<a class="bibr" href="#MAMABP186Re.REF.3" rid="MAMABP186Re.REF.3">3</a>). For this study, another NBP, [<sup>186</sup>Re]HEDP, was used as a control. The animals (<i>n</i> = 5–6 mice per time point) were euthanized at designated time points ranging from 10 min to 24 h postinjection (p.i.). Organs of interest (liver, kidney, blood, intestine, stomach, and the complete left femur) were removed from the cadavers and weighed, and the amount of radioactivity accumulated in the tissues was measured, and the data were presented as percent injected dose per gram tissue (% ID/g).</p><p>The tissue distribution pattern of radioactivity from [<sup>186</sup>Re]MAMA-BP was reported to be similar to that observed with [<sup>186</sup>Re]MAMA-HBP and [<sup>186</sup>Re]MAMA-HEDP (<a class="bibr" href="#MAMABP186Re.REF.3" rid="MAMABP186Re.REF.3">3</a>). Maximum label was deposited on the femur at all time points with the radiochemicals (21.38 ± 3.83% ID/g with [<sup>186</sup>Re]MAMA-BP, 24.80 ± 2.41% ID/g with [<sup>186</sup>Re]MAMA-HBP, and 13.09 ± 2.90% ID/g with [<sup>186</sup>Re]MAMA-HEDP) at 24 h p.i., followed by the kidneys (varying from 2.43 ± 0.53% ID/g with [<sup>186</sup>Re]MAMA-BP to 0.42 ± 0.10% ID/g with [<sup>186</sup>Re]MAMA-HEDP) at the same time point. The femur/blood ratios of radioactivity were ~1,200 with [<sup>186</sup>Re]MAMA-HBP compared with ~800 and ~400 with [<sup>186</sup>Re]MAMA-BP and [<sup>186</sup>Re]MAMA-HEDP, respectively. In addition, the blood clearance of radioactivity from [<sup>186</sup>Re]MAMA-HEDP was slower than that of the other two <sup>186</sup>Re-labeled MAMA-bisphosphonates, and it had a lower accumulation in the liver.</p><p>Ogawa et al. calculated the radiation dose estimates for the three bisphosphonates for adult patients by monoexponential extrapolation of the biodistribution data (<a class="bibr" href="#MAMABP186Re.REF.3" rid="MAMABP186Re.REF.3">3</a>). Although the red-marrow/bone-surface and total-body/bone-surface ratios for all the radiolabeled compounds were the same, the effective-dose/bone-surface ratio of [<sup>186</sup>Re]MAMA-HEDP was higher than that of either [<sup>186</sup>Re]MAMA-BP or [<sup>186</sup>Re]MAMA-HBP.</p></div><div id="MAMABP186Re.Other_NonPrimate_Mammals"><h3>Other Non-Primate Mammals</h3><p>[<a href="/pubmed?term=nitrogen%20containing%20bisphosphonates%20non%20primate%20mammal%20studies&cmd=DetailsSearch" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div><div id="MAMABP186Re.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/pubmed?term=nitrogen%20containing%20bisphosphonates%20non%20human%20primate%20studies&cmd=DetailsSearch" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div></div><div id="MAMABP186Re.Human_Studies"><h2 id="_MAMABP186Re_Human_Studies_">Human Studies</h2><p>[<a href="/pubmed?term=dipicolylamine-alendronate%20Human%20Studies&cmd=DetailsSearch" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div><div id="MAMABP186Re.Supplemental_Information"><h2 id="_MAMABP186Re_Supplemental_Information_">Supplemental Information</h2><p>[<a href="/books/n/micad/disclaimer/?report=reader">Disclaimers</a>]</p><p>No information is currently available.</p></div><div id="MAMABP186Re.References"><h2 id="_MAMABP186Re_References_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="MAMABP186Re.REF.1">Kimmel D.B.
|
|
<em>Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.</em>
|
|
<span><span class="ref-journal">J Dent Res. </span>2007;<span class="ref-vol">86</span>(11):1022–33.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17959891" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17959891</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="MAMABP186Re.REF.2">Drake M.T., Clarke B.L., Khosla S.
|
|
<em>Bisphosphonates: mechanism of action and role in clinical practice.</em>
|
|
<span><span class="ref-journal">Mayo Clin Proc. </span>2008;<span class="ref-vol">83</span>(9):1032–45.</span> [<a href="/pmc/articles/PMC2667901/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2667901</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18775204" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18775204</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="MAMABP186Re.REF.3">Ogawa K., Mukai T., Arano Y., Otaka A., Ueda M., Uehara T., Magata Y., Hashimoto K., Saji H.
|
|
<em>Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation.</em>
|
|
<span><span class="ref-journal">Nucl Med Biol. </span>2006;<span class="ref-vol">33</span>(4):513–20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16720243" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16720243</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="MAMABP186Re.REF.4">Torres Martin de Rosales R., Finucane C., Mather S.J., Blower P.J.
|
|
<em>Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases.</em>
|
|
<span><span class="ref-journal">Chem Commun (Camb). </span>2009;(32):4847–9.</span> [<a href="/pmc/articles/PMC7116767/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7116767</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19652801" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19652801</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="MAMABP186Re.REF.5">Chopra, A., <em>186Re-Labeled [N-2[[4-[(4-hydroxy-4,4-diphosphonobutyl)amino]-4-oxobutyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] conjugated to hydroxyl-bisphosphonate.</em> Molecular Imaging and Contrast agent Database (MICAD) [database online]. National Library of Medicine, NCBI, Bethesda, MD, USA. Available from <a href="http://www.micad.nih.gov/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">www<wbr style="display:inline-block"></wbr>​.micad.nih.gov</a>, 2004 -to current.</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="MAMABP186Re.REF.6">Ogawa K., Mukai T., Arano Y., Hanaoka H., Hashimoto K., Nishimura H., Saji H.
|
|
<em>Design of a radiopharmaceutical for the pallation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative.</em>
|
|
<span><span class="ref-journal">J. Label. Compd. Radiopharm. </span>2004;<span class="ref-vol">47</span>:753–761.</span></div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK44814_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Arvind Chopra</span>, PhD<div class="affiliation small">National Center for Biotechnology Information, NLM, NIH, Bethesda, MD 20894<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@dacim" class="oemail">vog.hin.mln.ibcn@dacim</a></div></div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">November 6, 2009</span>; Last Update: <span itemprop="dateModified">June 3, 2010</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Chopra A. 186Re-Labeled [N-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V) 2009 Nov 6 [Updated 2010 Jun 3]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/sos186re/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/MAMAHBP186Re/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobMAMABP186ReTncChemicalname186ReLabel"><div id="MAMABP186Re.T.nc_Chemical_name186ReLabel" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK44814/table/MAMABP186Re.T.nc_Chemical_name186ReLabel/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__MAMABP186Re.T.nc_Chemical_name186ReLabel_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>186</sup>Re-Labeled [<i>N</i>-[2[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethylenethiolate] oxorhenium (V)<br /></td><td rowspan="9" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/85281220" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=85281220" alt="image 85281220 in the ncbi pubchem database" /></a>
|
|
</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[<sup>186</sup>Re]MAMA-BP<br /></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compound</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hydroxyapatite: Bone imaging<br />Molecular target: Farnesyl disphosphate (pyrophosphate) synthase</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Enzyme</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Single-photon emission computed tomography (SPECT); gamma planar imaging</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal / contrast:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>186</sup>Re</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Click on the above structure of [<sup>186</sup>Re]MAMA-BP for additional information in <a href="http://pubchem.ncbi.nlm.nih.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubChem</a>.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|